Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants

被引：141

作者：

Bousman, Chad A. ^{[1
,2
,3
,4
,5
,6
]}

Stevenson, James M. ^{[7
,8
]}

Ramsey, Laura B. ^{[9
,10
,11
]}

Sangkuhl, Katrin ^{[12
]}

Hicks, J. Kevin ^{[13
]}

Strawn, Jeffrey R. ^{[11
,14
,15
]}

Singh, Ajeet B. ^{[16
]}

Ruano, Gualberto ^{[17
,18
]}

Mueller, Daniel J. ^{[19
,20
]}

Tsermpini, Evangelia Eirini ^{[21
]}

Brown, Jacob T. ^{[22
]}

Bell, Gillian C. ^{[23
]}

Leeder, J. Steven ^{[24
,25
]}

Gaedigk, Andrea ^{[24
,25
]}

Scott, Stuart A. ^{[26
,27
]}

Klein, Teri E.

Caudle, Kelly E. ^{[28
]}

Bishop, Jeffrey R. ^{[29
,30
]}

机构：

[1] Univ Calgary, Dept Med Genet, Calgary, AB, Canada

[2] Univ Calgary, Dept Psychiat, Calgary, AB, Canada

[3] Univ Calgary, Dept Physiol & Pharmacol, Calgary, AB, Canada

[4] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada

[5] Univ Calgary, Alberta Childrens Hosp Res Inst, Calgary, AB, Canada

[6] Univ Calgary, Hotchkiss Brain Inst, Mathison Ctr Mental Hlth Res & Educ, Calgary, AB, Canada

[7] Johns Hopkins Univ, Div Clin Pharmacol, Dept Med, Sch Med, Baltimore, MD USA

[8] Johns Hopkins Univ, Dept Pharmacol & Mol Sci, Sch Med, Baltimore, MD USA

[9] Univ Cincinnati, Dept Pediat, Coll Med, Cincinnati, OH USA

[10] Cincinnati Childrens Hosp Med Ctr, Div Clin Pharmacol, Cincinnati, OH USA

[11] Cincinnati Childrens Hosp Med Ctr, Div Patient Serv, Cincinnati, OH USA

[12] Stanford Univ, Dept Biomed Data Sci, Stanford, CA USA

[13] H Lee Moffitt Canc Ctr & Res Inst, Dept Individualized Canc Management, Tampa, FL USA

[14] Univ Cincinnati, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA

[15] Cincinnati Childrens Hosp Med Ctr, Div Child Adolescent Psychiat, Cincinnati, OH USA

[16] Deakin Univ, IMPACT Inst, Sch Med, Burwood, Vic, Australia

[17] Hartford Hosp, Inst Living, Hartford, CT USA

[18] Univ Connecticut, Dept Psychiat, Sch Med, Farmington, CT USA

[19] Ctr Addict & Mental Hlth, Campbell Family Mental Hlth Res Inst, Pharmacogenet Res Clin, Toronto, ON, Canada

[20] Univ Toronto, Dept Psychiat, Toronto, ON, Canada

[21] Univ Ljubljana, Inst Biochem & Mol Genet, Pharmacogenet Lab, Fac Med, Ljubljana, Slovenia

[22] Univ Minnesota, Dept Pharm Practice & Pharmaceut Sci, Coll Pharm, Duluth, MN USA

[23] Genome Med, South San Francisco, CA USA

[24] Childrens Mercy Res Inst, Div Clin Pharmacol Toxicol Therapeut Innovat, Kansas City, MO USA

[25] Univ Missouri Kansas City, Sch Med, Kansas City, MO USA

[26] Stanford Univ, Dept Pathol, Palo Alto, CA USA

[27] Stanford Med Clin Genom Program, Stanford, CA USA

[28] St Jude Childrens Res Hosp, Dept Pharm & Pharmaceut Sci, Memphis, TN USA

[29] Univ Minnesota, Dept Expt & Clin Pharmacol, Coll Pharm, Minneapolis, MN 55455 USA

[30] Univ Minnesota, Dept Psychiat & Behav Sci, Med Sch, Minneapolis, MN 55454 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2023年 / 114卷 / 01期

基金：

美国国家卫生研究院;

关键词：

PLASMA-CONCENTRATIONS; SERUM CONCENTRATIONS; GENETIC-VARIABILITY; QT PROLONGATION; IN-VITRO; EXPRESSION; POLYMORPHISMS; PAROXETINE; IMPACT; METAANALYSIS;

D O I：

10.1002/cpt.2903

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Serotonin reuptake inhibitor antidepressants, including selective serotonin reuptake inhibitors (SSRIs; i.e., citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline), serotonin and norepinephrine reuptake inhibitors (i.e., desvenlafaxine, duloxetine, levomilnacipran, milnacipran, and venlafaxine), and serotonin modulators with SSRI-like properties (i.e., vilazodone and vortioxetine) are primary pharmacologic treatments for major depressive and anxiety disorders. Genetic variation in CYP2D6, CYP2C19, and CYP2B6 influences the metabolism of many of these antidepressants, which may potentially affect dosing, efficacy, and tolerability. In addition, the pharmacodynamic genes SLC6A4 (serotonin transporter) and HTR2A (serotonin-2A receptor) have been examined in relation to efficacy and side effect profiles of these drugs. This guideline updates and expands the 2015 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and SSRI dosing and summarizes the impact of CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes on antidepressant dosing, efficacy, and tolerability. We provide recommendations for using CYP2D6, CYP2C19, and CYP2B6 genotype results to help inform prescribing these antidepressants and describe the existing data for SLC6A4 and HTR2A, which do not support their clinical use in antidepressant prescribing.

引用

页码：51 / 68

页数：18

共 52 条

[11] Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group
Caudle, Kelly E.
Sangkuhl, Katrin
Whirl-Carrillo, Michelle
Swen, Jesse J.
Haidar, Cyrine E.
Klein, Teri E.
Gammal, Roseann S.
Relling, Mary, V
Scott, Stuart A.
Hertz, Daniel L.
Guchelaar, Henk-Jan
Gaedigk, Andrea
[J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (01): : 116 - 124
[12] Polymorphisms in the CYP 2D6 gene: Association with plasma concentrations of fluoxetine and paroxetine
Charlier, C
Broly, F
Lhermitte, M
Pinto, E
Ansseau, M
Plomteux, G
[J]. THERAPEUTIC DRUG MONITORING, 2003, 25 (06) : 738 - 742
[13] Clinical Pharmacogenomics Implementation Consortium (CPIC), About us
[14] CPIC, CPIC GUID SEL SER RE
[15] Human hepatic CYP2B6 developmental expression: The impact of age and genotype
Croom, Edward L.
Stevens, Jeffrey C.
Hines, Ronald N.
Wallace, Andrew D.
Hodgson, Ernest
[J]. BIOCHEMICAL PHARMACOLOGY, 2009, 78 (02) : 184 - 190
[16] PharmVar GeneFocus: CYP2B6
Desta, Zeruesenay
El-Boraie, Ahmed
Gong, Li
Somogyi, Andrew A.
Lauschke, Volker M.
Dandara, Collet
Klein, Kathrin
Miller, Neil A.
Klein, Teri E.
Tyndale, Rachel F.
Whirl-Carrillo, Michelle
Gaedigk, Andrea
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (01) : 82 - 97
[17] COMPARISON OF NORFLUOXETINE ENANTIOMERS AS SEROTONIN UPTAKE INHIBITORS INVIVO
FULLER, RW
SNODDY, HD
KRUSHINSKI, JH
ROBERTSON, DW
[J]. NEUROPHARMACOLOGY, 1992, 31 (10) : 997 - 1000
[18] A Comparison of the Risk of QT Prolongation Among SSRIs
Funk, Kylee A.
Bostwick, Jolene R.
[J]. ANNALS OF PHARMACOTHERAPY, 2013, 47 (10) : 1330 - 1341
[19] Gex-Fabry M, 2008, THER DRUG MONIT, V30, P474, DOI 10.1097/FTD.0b013e31817d6f5d
[20] Güzey C, 2006, J CLIN PSYCHOPHARM, V26, P211

← 1 2 3 4 5 6 →